Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
Vinpocetine (Vin) existing oral formulations suffer poor bioavailability (∼7%) since Vin undergoes a marked first-pass effect (∼75%) and its absorption is dissolution rate-limited. In this study, a novel sustained release proniosomal system was designed using sugar esters (SEs) as non-ionic surfactants in which proniosomes were converted to niosomes upon skin water hydration following topical application under occlusive conditions. Different in vitro aspects (encapsulation efficiency, vesicle size and shape, effect of occlusion, in vitro release, skin permeation and stability) were studied leading to an optimized formula that was assessed clinically for transdermal pharmacokinetics and skin irritation. All formulae exhibited high entrapment efficiencies, regardless of the surfactant HLB. Vesicle size analysis showed that all vesicles were in the range from 0.63 μm to 2.52 μm which favored efficient transdermal delivery. The extent of drug permeation through the skin from the optimized formula--containing laurate SE with shorter fatty acid chain length and high HLB--was quite high (91%) after 48 h under occlusive conditions. The extent of absorption of Vin from proniosomes was larger when compared to the oral tablet with a relative bioavailability (F(rel)) of 206%. Histopathological evaluation revealed only moderate skin irritation when using SEs compared to skin inflammation when using Tween 80. Sugar esters proniosomes may be a promising carrier for vinpocetine, especially due to their simple scaling up and their ability to control drug release.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Egypt. hmellaithy@soficom.com.eg
Hanan M
HM
El-Laithy
Omar
O
Shoukry
Laila G
LG
Mahran
D000279:Administration, Cutaneous; D000328:Adult; D000818:Animals; D001682:Biological Availability; D055598:Chemical Phenomena; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000633:toxicity; D004339:Drug Compounding; D004355:Drug Stability; D006207:Half-Life; D006801:Humans; D008081:Liposomes / Q000737:chemistry* / Q000648:ultrastructure; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity; D010539:Permeability; D011817:Rabbits; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012869:Skin Absorption; D023422:Skin Irritancy Tests; D013501:Surface-Active Agents / Q000737:chemistry* / Q000633:toxicity; D014748:Vinca Alkaloids / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008081:Liposomes; D018696:Neuroprotective Agents; D013501:Surface-Active Agents; D014748:Vinca Alkaloids; C013983:vinpocetine